MX375348B - Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu. - Google Patents

Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.

Info

Publication number
MX375348B
MX375348B MX2014007042A MX2014007042A MX375348B MX 375348 B MX375348 B MX 375348B MX 2014007042 A MX2014007042 A MX 2014007042A MX 2014007042 A MX2014007042 A MX 2014007042A MX 375348 B MX375348 B MX 375348B
Authority
MX
Mexico
Prior art keywords
buprenorphine
opioid receptor
compositions
receptor antagonists
composition
Prior art date
Application number
MX2014007042A
Other languages
English (en)
Other versions
MX2014007042A (es
Inventor
Daniel Deaver
Elliot Ehrich
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of MX2014007042A publication Critical patent/MX2014007042A/es
Publication of MX375348B publication Critical patent/MX375348B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona a una composición que comprende buprenorfina y un antagonista del receptor opioide mu, en donde la composición se caracteriza por un índice de actividad de Antagonista-Agonista (AAnAI) de entre aproximadamente 0.7 y aproximadamente 2.2; en donde (ver Fórmula).
MX2014007042A 2011-12-15 2012-12-14 Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu. MX375348B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576233P 2011-12-15 2011-12-15
PCT/IB2012/002900 WO2013088243A1 (en) 2011-12-15 2012-12-14 Compositions of buprenorphine and mu-opioid receptor antagonists

Publications (2)

Publication Number Publication Date
MX2014007042A MX2014007042A (es) 2015-01-22
MX375348B true MX375348B (es) 2025-03-06

Family

ID=47757653

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014007042A MX375348B (es) 2011-12-15 2012-12-14 Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.
MX2020000270A MX391181B (es) 2011-12-15 2012-12-14 Composiciones de buprenorfina y antagonistas de los receptores opioide-mu

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020000270A MX391181B (es) 2011-12-15 2012-12-14 Composiciones de buprenorfina y antagonistas de los receptores opioide-mu

Country Status (25)

Country Link
US (8) US8822488B2 (es)
EP (3) EP3415148A1 (es)
JP (2) JP6038170B2 (es)
KR (1) KR101996108B1 (es)
CN (2) CN104159586A (es)
AU (1) AU2012351806C1 (es)
BR (1) BR112014012409B8 (es)
CA (1) CA2858812C (es)
CY (1) CY1121081T1 (es)
DK (1) DK3153171T3 (es)
EA (1) EA030609B8 (es)
ES (2) ES2692771T3 (es)
HR (1) HRP20181950T1 (es)
HU (1) HUE041883T2 (es)
IL (1) IL232785B (es)
LT (1) LT3153171T (es)
MX (2) MX375348B (es)
PL (1) PL3153171T3 (es)
PT (1) PT3153171T (es)
RS (1) RS58322B1 (es)
SI (1) SI3153171T1 (es)
SM (1) SMT201800664T1 (es)
TR (1) TR201815154T4 (es)
WO (1) WO2013088243A1 (es)
ZA (1) ZA201405029B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2729679T3 (es) 2009-12-04 2019-11-05 Alkermes Pharma Ireland Ltd Derivados de morfinano para el tratamiento de la sobredosis de fármacos
ES2705726T3 (es) 2010-08-23 2019-03-26 Alkermes Pharma Ireland Ltd Métodos para tratar el aumento de peso inducido por antipsicóticos
ES2692771T3 (es) * 2011-12-15 2018-12-05 Alkermes Pharma Ireland Limited Samidorfano (ALKS 33) en combinación con buprenorfina para el tratamiento de trastornos depresivos
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
JP2016519161A (ja) 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
EP3253747B1 (en) 2015-02-02 2019-11-27 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH581624A5 (es) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
TR199801348T2 (xx) 1996-01-10 1998-10-21 Smithkline Beecham S.P.A. Heterosikl-kondanse morfinoid t�revleri(II).
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
ES2572332T3 (es) 2000-10-31 2016-05-31 Rensselaer Polytech Inst 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
AU2003224742A1 (en) * 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
ATE308522T1 (de) 2002-05-30 2005-11-15 Lilly Co Eli Opioidrezeptorantagonisten
CN1984879B (zh) 2004-05-14 2011-07-27 詹森药业有限公司 甲酰胺基阿片样化合物
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
BRPI0517091B8 (pt) 2004-11-05 2021-05-25 Rensselaer Polytech Inst composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
PT1856093E (pt) 2005-03-02 2010-02-08 Nycomed Gmbh Sal hcl de (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-etoxi- 8-metoxi-1,2,3,4,4a,10b-hexa-hidrofenantridin-2-ol
PL2134330T3 (pl) 2007-03-19 2013-10-31 Acadia Pharm Inc Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami
BRPI0815020A2 (pt) 2007-08-09 2015-03-10 Rensselaer Polytech Inst Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia.
TR201809734T4 (tr) * 2008-02-14 2018-07-23 Alkermes Inc Seçici opioid bileşikler.
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
EP3170395A1 (en) * 2009-03-19 2017-05-24 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
WO2010141666A2 (en) 2009-06-04 2010-12-09 The General Hospital Corporation Modulating endogenous beta-endorphin levels
US8530479B2 (en) * 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
ES2729679T3 (es) * 2009-12-04 2019-11-05 Alkermes Pharma Ireland Ltd Derivados de morfinano para el tratamiento de la sobredosis de fármacos
US9211293B2 (en) * 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
ES2692771T3 (es) * 2011-12-15 2018-12-05 Alkermes Pharma Ireland Limited Samidorfano (ALKS 33) en combinación con buprenorfina para el tratamiento de trastornos depresivos
EP3003311A2 (en) * 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms

Also Published As

Publication number Publication date
MX2014007042A (es) 2015-01-22
HRP20181950T1 (hr) 2019-03-22
RS58322B1 (sr) 2019-03-29
US8822488B2 (en) 2014-09-02
US10314838B2 (en) 2019-06-11
PL3153171T3 (pl) 2019-02-28
JP2016222706A (ja) 2016-12-28
KR101996108B1 (ko) 2019-10-01
US20130190342A1 (en) 2013-07-25
EP3153171B1 (en) 2018-09-19
US20180078542A1 (en) 2018-03-22
MX391181B (es) 2025-03-21
US10806731B2 (en) 2020-10-20
AU2012351806C1 (en) 2016-06-16
EP3415148A1 (en) 2018-12-19
US9498474B2 (en) 2016-11-22
US9913837B2 (en) 2018-03-13
EA030609B8 (ru) 2018-10-31
EP2790702B1 (en) 2020-04-01
CY1121081T1 (el) 2019-12-11
BR112014012409A2 (pt) 2017-06-13
BR112014012409B8 (pt) 2022-09-13
LT3153171T (lt) 2018-12-10
IL232785A0 (en) 2014-07-31
EP3153171A1 (en) 2017-04-12
TR201815154T4 (tr) 2018-11-21
JP6038170B2 (ja) 2016-12-07
AU2012351806B2 (en) 2016-03-10
WO2013088243A1 (en) 2013-06-20
EA030609B1 (ru) 2018-08-31
EA201491153A1 (ru) 2015-04-30
CN106727562B (zh) 2019-07-05
BR112014012409B1 (pt) 2022-08-23
US20210196703A1 (en) 2021-07-01
PT3153171T (pt) 2018-11-16
ES2791764T3 (es) 2020-11-05
HUE041883T2 (hu) 2019-06-28
SI3153171T1 (sl) 2019-01-31
DK3153171T3 (en) 2018-11-19
CA2858812C (en) 2019-02-26
ES2692771T3 (es) 2018-12-05
US20150051240A1 (en) 2015-02-19
ZA201405029B (en) 2015-10-28
JP2015505853A (ja) 2015-02-26
EP2790702A1 (en) 2014-10-22
JP6403726B2 (ja) 2018-10-10
SMT201800664T1 (it) 2019-01-11
KR20140107258A (ko) 2014-09-04
NZ624056A (en) 2016-07-29
US20170056392A1 (en) 2017-03-02
AU2012351806A1 (en) 2014-05-15
US9918978B2 (en) 2018-03-20
US10188643B2 (en) 2019-01-29
CA2858812A1 (en) 2013-06-20
US20180078543A1 (en) 2018-03-22
US20160256450A1 (en) 2016-09-08
IL232785B (en) 2021-04-29
CN106727562A (zh) 2017-05-31
CN104159586A (zh) 2014-11-19
US20190247387A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
MX375348B (es) Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2680697A4 (en) PROCESS FOR PREPARING AN OREXINE RECEPTOR ANTAGONIST
EP2934527A4 (en) 2-pyridyloxy-4-ESTER-orexin receptor antagonists
MY172806A (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
EP2925321A4 (en) 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
EP2771001A4 (en) PIPERIDINYL-alkyne-orexin
EA201490037A1 (ru) Антагонисты trpv4
PA8774201A1 (es) Antagonista del receptor
MX2011011156A (es) COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
MY160665A (en) Spiropiperidine compounds as orl-1 receptor antagonists
MX2009010515A (es) Antagonistas del receptor opioide periferico y usos de los mismos.
MY150062A (en) Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
MX350419B (es) Compuesto (tieno [2,3-b] [1,5] benzoxazepin -4 -il) piperazin- 1 - ilo como angonistas inversos h1/antagonistas 5 -ht2a de actividad doble.
SMT201500068B (it) Nuovi analoghi di piperazina come antivirali ad ampio spettro per l'influenza
DOP2011000017A (es) Compuestos novedosos activos como antagonistas de receptor muscarinico
UA110039C2 (xx) СПОЛУКИ 4-ЗАМІЩЕНОГО 3-ФЕНІЛСУЛЬФАНІЛМЕТИЛБІЦИКЛО$3.1.0]ГЕКСАНУ ЯК АНТАГОНІСТИ mGluR 2/3
EP2539706A4 (en) ARYLPIPERAZON-OPIOID RECEPTOR ANTAGONISTS
MX341132B (es) Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble.
EA201390568A1 (ru) СОЕДИНЕНИЯ 4-ЗАМЕЩЕННОГО-3-БЕНЗИЛОКСИБИЦИКЛО[3.1.0]ГЕКСАНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGLuR 2/3

Legal Events

Date Code Title Description
FG Grant or registration